Does the media refer more to BEAM or NTLA?

In the previous week, Beam Therapeutics had 8 more articles in the media than Intellia Therapeutics. MarketBeat recorded 27 mentions for Beam Therapeutics and 19 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.51 beat Beam Therapeutics' score of 0.48 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or NTLA?

In the previous week, Intellia Therapeutics had 12 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Intellia Therapeutics and 7 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Intellia Therapeutics' score of 0.51 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or NTLA?

In the previous week, Intellia Therapeutics had 7 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Intellia Therapeutics and 12 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.80 beat Intellia Therapeutics' score of 0.51 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or RYTM?

In the previous week, Intellia Therapeutics had 13 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Intellia Therapeutics and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.63 beat Intellia Therapeutics' score of 0.51 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NTLA or SRRK?

In the previous week, Intellia Therapeutics had 7 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for Intellia Therapeutics and 12 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.71 beat Intellia Therapeutics' score of 0.51 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$11.74 -0.19 (-1.59%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$11.78 +0.04 (+0.38%)

As of 09/11/2026 07:49 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, RYTM, and SRRK

Should you buy Intellia Therapeutics stock or one of its competitors? Intellia Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Rhythm Pharmaceuticals (RYTM), and Scholar Rock (SRRK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	17.73	-$79.99M	-$0.86	N/A
Intellia Therapeutics	$67.67M	24.31	-$412.69M	-$3.36	N/A

In the previous week, Beam Therapeutics had 8 more articles in the media than Intellia Therapeutics. MarketBeat recorded 27 mentions for Beam Therapeutics and 19 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.51 beat Beam Therapeutics' score of 0.48 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -54.75% compared to Intellia Therapeutics' net margin of -672.16%. Beam Therapeutics' return on equity of -30.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Beam Therapeutics currently has a consensus target price of $49.00, suggesting a potential upside of 104.25%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 78.69%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Beam Therapeutics has a beta of 2.22, suggesting that its stock price is 122% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market.

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Intellia Therapeutics has a net margin of -672.16% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

CRISPR Therapeutics presently has a consensus target price of $68.06, suggesting a potential upside of 31.58%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 78.69%. Given Intellia Therapeutics' higher possible upside, analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,424.73	-$581.60M	-$4.76	N/A
Intellia Therapeutics	$67.67M	24.31	-$412.69M	-$3.36	N/A

In the previous week, Intellia Therapeutics had 12 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 19 mentions for Intellia Therapeutics and 7 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Intellia Therapeutics' score of 0.51 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	10.23	-$160.06M	-$0.75	N/A
Intellia Therapeutics	$67.67M	24.31	-$412.69M	-$3.36	N/A

Editas Medicine has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 7 more articles in the media than Editas Medicine. MarketBeat recorded 19 mentions for Intellia Therapeutics and 12 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.80 beat Intellia Therapeutics' score of 0.51 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Editas Medicine currently has a consensus target price of $6.00, suggesting a potential upside of 122.22%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 78.69%. Given Editas Medicine's stronger consensus rating and higher probable upside, research analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Rhythm Pharmaceuticals?

Intellia Therapeutics (NASDAQ:NTLA) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Intellia Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Intellia Therapeutics currently has a consensus target price of $20.98, suggesting a potential upside of 78.69%. Rhythm Pharmaceuticals has a consensus target price of $141.12, suggesting a potential upside of 34.77%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74

88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 13 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 19 mentions for Intellia Therapeutics and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.63 beat Intellia Therapeutics' score of 0.51 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	24.31	-$412.69M	-$3.36	N/A
Rhythm Pharmaceuticals	$189.76M	37.82	-$196.54M	-$3.11	N/A

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Summary

Rhythm Pharmaceuticals beats Intellia Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Intellia Therapeutics compare to Scholar Rock?

Intellia Therapeutics (NASDAQ:NTLA) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Comparatively, 10.3% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Intellia Therapeutics had 7 more articles in the media than Scholar Rock. MarketBeat recorded 19 mentions for Intellia Therapeutics and 12 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.71 beat Intellia Therapeutics' score of 0.51 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics presently has a consensus price target of $20.98, suggesting a potential upside of 78.69%. Scholar Rock has a consensus price target of $58.77, suggesting a potential upside of 6.06%. Given Intellia Therapeutics' higher possible upside, equities research analysts clearly believe Intellia Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06

Scholar Rock has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Scholar Rock	N/A	-160.19%	-87.18%

Intellia Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Scholar Rock has lower revenue, but higher earnings than Intellia Therapeutics. Scholar Rock is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	24.31	-$412.69M	-$3.36	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Summary

Intellia Therapeutics beats Scholar Rock on 8 of the 15 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.65B	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-3.49	14.18	274.94	25.36
Price / Sales	24.31	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	2.02	15.12	10.33	6.20
Net Income	-$412.69M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.85%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.76%	0.54%	-0.53%	-3.23%
1 Year Performance	2.80%	40.74%	23.51%	8.79%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.0548 of 5 stars	$11.74 -1.6%	$20.98 +78.7%	+2.8%	$1.65B	$67.67M	N/A	377	Analyst Forecast
BEAM Beam Therapeutics	2.3517 of 5 stars	$29.66 flat	$49.00 +65.2%	+16.5%	$3.06B	$139.74M	N/A	510	Trending News Analyst Forecast Options Volume
CRSP CRISPR Therapeutics	2.3633 of 5 stars	$55.79 flat	$68.06 +22.0%	-8.1%	$5.39B	$3.51M	N/A	460
EDIT Editas Medicine	2.2895 of 5 stars	$3.23 flat	$6.00 +85.8%	+0.4%	$496.06M	$40.52M	N/A	230	News Coverage Gap Down
RYTM Rhythm Pharmaceuticals	2.5608 of 5 stars	$102.74 flat	$141.12 +37.4%	+8.8%	$7.04B	$189.76M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, RYTM, and SRRK

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Intellia Therapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, RYTM, and SRRK

How does Intellia Therapeutics compare to Beam Therapeutics?

Which has stronger earnings and valuation, BEAM or NTLA?

Does the media refer more to BEAM or NTLA?

Is BEAM or NTLA more profitable?

Do analysts prefer BEAM or NTLA?

Do institutionals & insiders believe in BEAM or NTLA?

Which has more volatility & risk, BEAM or NTLA?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Is CRSP or NTLA more profitable?

Which has more volatility & risk, CRSP or NTLA?

Do analysts prefer CRSP or NTLA?

Do insiders & institutionals have more ownership in CRSP or NTLA?

Which has higher valuation & earnings, CRSP or NTLA?

Does the media favor CRSP or NTLA?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Do insiders and institutionals have more ownership in EDIT or NTLA?

Is EDIT or NTLA more profitable?

Which has preferable earnings and valuation, EDIT or NTLA?

Which has more volatility and risk, EDIT or NTLA?

Does the media favor EDIT or NTLA?

Do analysts prefer EDIT or NTLA?

Summary

How does Intellia Therapeutics compare to Rhythm Pharmaceuticals?

Which has more risk and volatility, NTLA or RYTM?

Do analysts recommend NTLA or RYTM?

Do institutionals & insiders hold more shares of NTLA or RYTM?

Does the media refer more to NTLA or RYTM?

Which has better earnings and valuation, NTLA or RYTM?

Is NTLA or RYTM more profitable?

Summary

How does Intellia Therapeutics compare to Scholar Rock?

Do insiders & institutionals hold more shares of NTLA or SRRK?

Does the media prefer NTLA or SRRK?

Do analysts rate NTLA or SRRK?

Is NTLA or SRRK more profitable?

Which has more volatility & risk, NTLA or SRRK?

Which has preferable valuation & earnings, NTLA or SRRK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools